{{Drugbox
| IUPAC_name = 4-(naphthalen-2-ylmethoxy)piperidine
| image = Litoxetine-2D-skeletal.png

<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!--Identifiers-->
| CAS_number = 86811-09-8
| ATC_prefix = None
| ATC_suffix = 
| PubChem = 65650
| ChemSpiderID = 59087
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9980ST005G
| ChEMBL = 471036
| synonyms = SL 81-0385; IXA-001

<!--Chemical data-->
| C=16 | H=19 | N=1 | O=1 
| molecular_weight = 241.327 g/mol
| SMILES = C3CNCCC3OCc2cc1ccccc1cc2
}}

'''Litoxetine''' (developmental code names '''SL 81-0385''', '''IXA-001''') is an [[antidepressant]] which was under clinical development for the treatment of [[major depression|depression]] in the early 1990s but was never marketed.<ref name="AdisInsight">http://adisinsight.springer.com/drugs/800001264</ref><ref name="pmid8562293">{{cite journal |vauthors=Fairweather DB, Patat A, Rosenzweig P, Curson VH, Dunmore C, Dubruc C, Hindmarch I |title=The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers |journal=British Journal of Clinical Pharmacology |volume=40 |issue=2 |pages=119–25 |date=August 1995 |pmid=8562293 |pmc=1365170 |doi= 10.1111/j.1365-2125.1995.tb05767.x|url=}}</ref> It acts as a [[potency (pharmacology)|potent]] [[serotonin reuptake inhibitor]] (K<sub>i</sub> for {{abbrlink|SERT|serotonin transporter}} = 7&nbsp;nM) and modest [[5-HT3|5-HT<sub>3</sub> receptor]] [[receptor antagonist|antagonist]] (K<sub>i</sub> = 315&nbsp;nM).<ref name="RankovicHargreaves2012">{{cite book|author1=Zoran Rankovic|author2=Richard Hargreaves|author3=Matilda Bingham|title=Drug Discovery for Psychiatric Disorders|url=https://books.google.com/books?id=e3YoDwAAQBAJ&pg=PA195|date=8 October 2012|publisher=Royal Society of Chemistry|isbn=978-1-84973-494-3|pages=195–}}</ref><ref name="Birkhäuser2012">{{cite book|title=Progress in Drug Research|url=https://books.google.com/books?id=-d8FCAAAQBAJ&pg=PA80|date=6 December 2012|publisher=Birkhäuser|isbn=978-3-0348-8391-7|pages=80–}}</ref> It has [[antiemetic]] activity, and unlike the [[selective serotonin reuptake inhibitor]]s (SSRIs), appears to have a negligible incidence of [[nausea]] and [[vomiting]].<ref name="pmid8385615">{{cite journal |vauthors=Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ |title=Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties |journal=European Journal of Pharmacology |volume=232 |issue=2-3 |pages=139–45 |date=March 1993 |pmid=8385615 |doi= 10.1016/0014-2999(93)90767-C|url=}}</ref> The drug is structurally related to [[indalpine]].<ref name="Birkhäuser2012" /> Development of litoxetine for depression was apparently ceased in the late 1990s.<ref name="AdisInsight" /> However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the [[Phases of clinical research#Phase II|phase II]] stage for the treatment of [[urinary incontinence]].<ref name="AdisInsight" />

==References==
{{Reflist|2}}

==External links==
* [http://adisinsight.springer.com/drugs/800001264 Litoxetine - AdisInsight]

{{Monoamine reuptake inhibitors}}
{{Serotonin receptor modulators}}

[[Category:5-HT3 antagonists]]
[[Category:Antidepressants]]
[[Category:Ethers]]
[[Category:Naphthalenes]]
[[Category:Piperidines]]
[[Category:Serotonin reuptake inhibitors]]